ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases. SDB includes obstructive sleep apnea (OSA) and other respiratory disorders that occur during sleep. Its cloud-based software digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, portable oxygen concentrators (POCs) and cloud-based software informatics solutions. The Company produces Continuous Positive Airway Pressure (CPAP), Variable Positive Airway Pressure (VPAP) and AutoSet systems for the titration and treatment of SDB.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:RMD
CUSIP76115210
Phone858-836-5000
Debt
Debt-to-Equity RatioN/A
Current Ratio1.29%
Quick Ratio1.08%
Price-To-Earnings
Trailing P/E Ratio34.24
Forward P/E Ratio28.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.07 billion
Price / Sales6.68
Cash Flow$3.5383 per share
Price / Cash27.29
Book Value$13.82 per share
Price / Book6.99
Profitability
EPS (Most Recent Fiscal Year)$2.82
Net Income$342.28 million
Net Margins12.98%
Return on Equity22.75%
Return on Assets12.86%
Miscellaneous
Employees6,080
Outstanding Shares142,930,000
ResMed (NYSE:RMD) Frequently Asked Questions
What is ResMed's stock symbol?
ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."
How often does ResMed pay dividends? What is the dividend yield for ResMed?
ResMed announced a quarterly dividend on Monday, January 22nd. Investors of record on Thursday, February 8th will be paid a dividend of $0.35 per share on Thursday, March 15th. This represents a $1.40 annualized dividend and a yield of 1.45%. The ex-dividend date is Wednesday, February 7th. View ResMed's Dividend History.
How were ResMed's earnings last quarter?
ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Monday, January, 22nd. The medical equipment provider reported $1.00 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.78 by $0.22. The medical equipment provider earned $601.27 million during the quarter, compared to analysts' expectations of $583.77 million. ResMed had a return on equity of 22.75% and a net margin of 12.98%. The company's revenue was up 13.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.73 earnings per share. View ResMed's Earnings History.
When is ResMed's next earnings date?
What price target have analysts set for RMD?
12 analysts have issued 1-year price objectives for ResMed's shares. Their forecasts range from $55.00 to $90.00. On average, they anticipate ResMed's stock price to reach $68.80 in the next twelve months. View Analyst Ratings for ResMed.
What are Wall Street analysts saying about ResMed stock?
Here are some recent quotes from research analysts about ResMed stock:
- 1. According to Zacks Investment Research, "Over the past three months, ResMed has outperformed its industry. We are encouraged to note that ResMed is working on product innovation through extensive research and development. Brightree has started to strongly contribute to the company’s operating results based on product developments. Among the latest developments, the company recently informed about its first self-branded portable oxygen concentrator Mobi, subject to a fiscal third-quarter launch. It has also introduced AirMini, the world's smallest PAP device. Moreover, the company achieved solid double-digit global revenue growth in the last reported quarter, led by sales from Software-as-a-Service business as well as mask products and devices. Yet, challenges like competitive bidding and reimbursement issues continue to plague ResMed. The company also remains exposed to challenging pricing scenario. Rising costs and a weak gross margin are other concerns." (4/9/2018)
- 2. Needham & Company LLC analysts commented, "We worked with Sleep Review magazine to survey US sleep centers. The survey included 136 responses received between 1/30/18 and 2/19/18. Compared to our prior (3Q17) survey, actual last-12-month patient volume growth decreased slightly while expected next-12-month patient volume growth increased slightly. RMD’s flow generator ratings were in line with Respironics’ ratings while RMD’s mask ratings were the highest but only slightly above its competitors’ ratings. RMD looks likely to gain branded flow generator prescription share but to lose branded mask prescription share. Overall, we think that the survey is mixed for RMD and we maintain our Hold rating." (3/7/2018)
Who are some of ResMed's key competitors?
Some companies that are related to ResMed include Fresenius (FSNUY), Boston Scientific (BSX), Baxter International (BAX), Abiomed (ABMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Insulet (PODD), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), NuVasive (NUVA) and Nevro (NVRO).
Who are ResMed's key executives?
ResMed's management team includes the folowing people:
- Peter C. Farrell Ph.D., Non-Executive Chairman of the Board, Founder (Age 75)
- Rob Douglas, President, Chief Operating Officer (Age 57)
- Michael Farrell, Chief Executive Officer, Director (Age 45)
- Brett A. Sandercock, Chief Financial Officer (Age 50)
- Jim Hollingshead Ph.D., President – Sleep Business (Age 54)
- Richard McHale, President – Respiratory Care (Age 53)
- Raj Sodhi, President – Software as a Service (SaaS) Business and Chief Technology Officer (Age 44)
- David Pendarvis, Chief Administrative Officer, Global General Counsel, Company Secretary (Age 57)
- Ronald R. Taylor, Lead Independent Director (Age 69)
- Karen Drexler, Director (Age 56)
Has ResMed been receiving favorable news coverage?
News articles about RMD stock have trended somewhat positive this week, Accern reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ResMed earned a daily sentiment score of 0.22 on Accern's scale. They also assigned news stories about the medical equipment provider an impact score of 48.13 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of ResMed?
Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ResMed's stock price today?
One share of RMD stock can currently be purchased for approximately $96.56.
How big of a company is ResMed?
ResMed has a market capitalization of $14.12 billion and generates $2.07 billion in revenue each year. The medical equipment provider earns $342.28 million in net income (profit) each year or $2.82 on an earnings per share basis. ResMed employs 6,080 workers across the globe.
How can I contact ResMed?
ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at investorrelati[email protected]
MarketBeat Community Rating for ResMed (RMD)
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
ResMed (NYSE:RMD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for ResMed in the last 12 months. Their average twelve-month price target is $68.80, suggesting that the stock has a possible downside of 28.75%. The high price target for RMD is $90.00 and the low price target for RMD is $55.00. There are currently 3 sell ratings, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 1.92 | 2.00 | 2.00 | 1.90 |
| Ratings Breakdown: | 3 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $68.80 | $68.80 | $67.1667 | $64.80 |
| Price Target Upside: | 28.75% downside | 28.47% downside | 23.25% downside | 15.35% downside |
ResMed (NYSE:RMD) Consensus Price Target History
ResMed (NYSE:RMD) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
ResMed (NYSE:RMD) Dividend Information
ResMed pays an annual dividend of $1.40 per share, with a dividend yield of 1.45%. RMD's most recent quarterly dividend payment was Thursday, March 15. The company has grown its dividend for the last 2 consecutive years and is increasing its dividend by an average of 8.70% each year. ResMed pays out 49.65% of its earnings out as a dividend.
| Most Recent Dividend: | 3/15/2018 |
| Annual Dividend: | $1.40 |
| Dividend Yield: | 1.45% |
| Dividend Growth: | 8.70% (3 Year Average) |
| Payout Ratio: | 49.65% (Trailing 12 Months of Earnings)
41.42% (Based on This Year's Estimates)
39.89% (Based on Next Year's Estimates)
|
| Track Record: | 2 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
ResMed (NYSE:RMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 1/22/2018 | quarterly | $0.35 | 1.42% | 2/7/2018 | 2/8/2018 | 3/15/2018 |
| 10/26/2017 | quarterly | $0.35 | 1.66% | 11/8/2017 | 11/9/2017 | 12/14/2017 |
| 8/2/2017 | quarterly | $0.35 | 1.93% | 8/15/2017 | 8/17/2017 | 9/21/2017 |
| 4/27/2017 | quarterly | $0.33 | 1.94% | 5/9/2017 | 5/11/2017 | 6/15/2017 |
| 1/23/2017 | quarterly | $0.33 | 1.89% | 2/7/2017 | 2/9/2017 | 3/16/2017 |
| 10/25/2016 | quarterly | $0.33 | 2.18% | 11/8/2016 | 11/10/2016 | 12/15/2016 |
| 7/28/2016 | quarterly | $0.33 | 1.92% | 8/16/2016 | 8/18/2016 | 9/22/2016 |
| 4/26/2016 | quarterly | $0.30 | 2.12% | 5/17/2016 | 5/19/2016 | 6/16/2016 |
| 1/21/2016 | quarterly | $0.30 | 2.08% | 2/9/2016 | 2/11/2016 | 3/17/2016 |
| 10/22/2015 | quarterly | $0.30 | 2.13% | 11/17/2015 | 11/19/2015 | 12/17/2015 |
| 7/30/2015 | quarterly | $0.30 | 2.07% | 8/18/2015 | 8/20/2015 | 9/17/2015 |
| 4/24/2015 | quarterly | $0.28 | 1.7% | 5/19/2015 | 5/21/2015 | 6/18/2015 |
| 1/23/2015 | quarterly | $0.28 | 1.72% | 2/10/2015 | 2/12/2015 | 3/19/2015 |
| 10/27/2014 | quarterly | $0.28 | 2.17% | 11/18/2014 | 11/20/2014 | 12/18/2014 |
| 8/1/2014 | quarterly | $0.28 | 2.25% | 8/19/2014 | 8/21/2014 | 9/18/2014 |
| 4/24/2014 | quarterly | $0.25 | 2.11% | 5/16/2014 | 5/20/2014 | 6/17/2014 |
| 1/24/2014 | quarterly | $0.25 | 2.28% | 2/14/2014 | 2/19/2014 | 3/19/2014 |
| 10/25/2013 | quarterly | $0.25 | 2.02% | 11/15/2013 | 11/19/2013 | 12/18/2013 |
| 8/2/2013 | quarterly | $0.25 | 2.09% | 8/16/2013 | 8/20/2013 | 9/17/2013 |
| 4/29/2013 | quarterly | $0.17 | 1.44% | 5/17/2013 | 5/21/2013 | 6/18/2013 |
| 1/25/2013 | quarterly | $0.17 | 1.41% | 2/14/2013 | 2/19/2013 | 3/19/2013 |
(Data available from 1/1/2013 forward)
ResMed (NYSE RMD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.77%
Institutional Ownership Percentage: 62.38%
ResMed (NYSE RMD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Brett Sandercock | CFO | Sell | 2,000 | $99.36 | $198,720.00 | 71,072 |  |
| 4/2/2018 | James Hollingshead | Insider | Sell | 600 | $98.19 | $58,914.00 | 59,940 | |
| 3/15/2018 | Brett Sandercock | CFO | Sell | 2,000 | $98.53 | $197,060.00 | 73,072 | |
| 3/5/2018 | David Pendarvis | Insider | Sell | 2,810 | $94.08 | $264,364.80 | 97,263 | |
| 3/1/2018 | James Hollingshead | Insider | Sell | 600 | $94.01 | $56,406.00 | | |
| 2/15/2018 | Brett Sandercock | CFO | Sell | 2,000 | $93.42 | $186,840.00 | 75,072 | |
| 2/5/2018 | David Pendarvis | Insider | Sell | 2,810 | $96.03 | $269,844.30 | 97,263 | |
| 2/1/2018 | Brett Sandercock | CFO | Sell | 1,250 | $100.13 | $125,162.50 | 77,072 | |
| 2/1/2018 | Richard Mchale | Insider | Sell | 2,000 | $100.12 | $200,240.00 | 62,002 | |
| 1/26/2018 | John P Wareham | Director | Sell | 25,934 | $102.25 | $2,651,751.50 | 38,934 | |
| 1/24/2018 | Ronald R Taylor | Director | Sell | 4,885 | $99.71 | $487,083.35 | 21,751 | |
| 1/2/2018 | Brett Sandercock | CFO | Sell | 1,250 | $84.99 | $106,237.50 | 78,322 | |
| 1/2/2018 | James Hollingshead | Insider | Sell | 600 | $84.96 | $50,976.00 | 62,602 | |
| 12/4/2017 | David Pendarvis | Insider | Sell | 2,804 | $84.17 | $236,012.68 | 97,257 | |
| 12/1/2017 | Brett Sandercock | CFO | Sell | 1,250 | $85.36 | $106,700.00 | 79,572 | |
| 11/20/2017 | James Hollingshead | Insider | Sell | 7,019 | $84.16 | $590,719.04 | 66,409 | |
| 11/9/2017 | Peter C Farrell | Director | Sell | 118,392 | $82.70 | $9,791,018.40 | 306,615 | |
| 11/6/2017 | Peter C Farrell | Director | Sell | 20,000 | $83.53 | $1,670,600.00 | 314,800 | |
| 11/3/2017 | David Pendarvis | Insider | Sell | 6,364 | $82.20 | $523,120.80 | | |
| 11/1/2017 | Brett Sandercock | CFO | Sell | 1,250 | $84.50 | $105,625.00 | 71,772 | |
| 10/4/2017 | Peter C Farrell | Director | Sell | 20,000 | $77.01 | $1,540,200.00 | | |
| 10/3/2017 | David Pendarvis | Insider | Sell | 6,364 | $76.94 | $489,646.16 | | |
| 10/2/2017 | Brett Sandercock | CFO | Sell | 1,250 | $77.05 | $96,312.50 | 64,691 | |
| 9/5/2017 | David Pendarvis | Insider | Sell | 6,364 | $77.21 | $491,364.44 | 93,172 | |
| 9/5/2017 | Peter C Farrell | Director | Sell | 20,000 | $76.74 | $1,534,800.00 | 314,800 | |
| 9/1/2017 | Brett Sandercock | CFO | Sell | 1,250 | $77.56 | $96,950.00 | 65,941 | |
| 8/9/2017 | Richard Sulpizio | Director | Sell | 24,390 | $73.85 | $1,801,201.50 | 28,819 | |
| 8/4/2017 | Peter C Farrell | Director | Sell | 20,000 | $75.15 | $1,503,000.00 | 321,557 | |
| 8/3/2017 | David Pendarvis | Insider | Sell | 6,364 | $72.10 | $458,844.40 | 84,476 | |
| 8/1/2017 | Brett Sandercock | CFO | Sell | 1,250 | $77.49 | $96,862.50 | 59,258 | |
| 7/14/2017 | James Hollingshead | Insider | Sell | 7,140 | $77.43 | $552,850.20 | | |
| 7/5/2017 | Peter C Farrell | Director | Sell | 20,000 | $76.50 | $1,530,000.00 | 321,557 | |
| 7/3/2017 | Brett Sandercock | CFO | Sell | 1,250 | $77.44 | $96,800.00 | 60,508 | |
| 7/3/2017 | David Pendarvis | Insider | Sell | 6,364 | $77.36 | $492,319.04 | 84,476 | |
| 6/29/2017 | Jr. Gregor K Emmert | Insider | Buy | 282,000 | $0.07 | $19,740.00 | | |
| 6/28/2017 | Jr. Gregor K Emmert | Insider | Buy | 424,000 | $0.06 | $25,440.00 | | |
| 6/22/2017 | Richard Sulpizio | Director | Sell | 65,887 | $77.82 | $5,127,326.34 | 4,429 | |
| 6/15/2017 | Gary W Pace | Director | Sell | 24,390 | $76.00 | $1,853,640.00 | 99,317 | |
| 6/5/2017 | David Pendarvis | Insider | Sell | 6,365 | $72.62 | $462,226.30 | 84,477 | |
| 6/5/2017 | Peter C Farrell | Director | Sell | 20,000 | $72.65 | $1,453,000.00 | 321,557 | |
| 6/1/2017 | Brett Sandercock | CFO | Sell | 1,250 | $71.02 | $88,775.00 | | |
| 5/4/2017 | Peter C Farrell | Director | Sell | 20,000 | $68.75 | $1,375,000.00 | 321,557 | |
| 5/3/2017 | David Pendarvis | Insider | Sell | 6,365 | $69.55 | $442,685.75 | 84,261 | |
| 5/1/2017 | Brett Sandercock | CFO | Sell | 1,250 | $68.60 | $85,750.00 | 62,783 | |
| 4/17/2017 | James Hollingshead | Insider | Sell | 7,139 | $68.37 | $488,093.43 | 44,934 | |
| 4/4/2017 | Peter C Farrell | Director | Sell | 20,000 | $70.67 | $1,413,400.00 | 321,557 | |
| 4/3/2017 | Brett Sandercock | CFO | Sell | 1,250 | $71.65 | $89,562.50 | 64,033 | |
| 4/3/2017 | David Pendarvis | Insider | Sell | 6,365 | $71.59 | $455,670.35 | 84,261 | |
| 3/1/2017 | Brett Sandercock | CFO | Sell | 1,250 | $72.48 | $90,600.00 | 65,283 | |
| 2/24/2017 | John P Wareham | Director | Sell | 28,403 | $71.77 | $2,038,483.31 | 41,403 | |
| 2/20/2017 | Christopher G Roberts | Director | Sell | 10,000 | $71.91 | $719,100.00 | 145,610 | |
| 2/15/2017 | Franz Kozich | Director | Buy | 50,000 | $0.05 | $2,500.00 | | |
| 2/14/2017 | Warren Russell Hawkins | Director | Buy | 60,000 | $0.05 | $3,000.00 | | |
| 2/6/2017 | Peter C Farrell | Director | Sell | 20,000 | $68.32 | $1,366,400.00 | 321,557 | |
| 2/3/2017 | David Pendarvis | Insider | Sell | 6,365 | $67.16 | $427,473.40 | 84,261 | |
| 1/17/2017 | James Hollingshead | Insider | Sell | 7,084 | $64.44 | $456,492.96 | 46,754 | |
| 1/4/2017 | Peter C Farrell | Director | Sell | 20,000 | $62.14 | $1,242,800.00 | 321,557 | |
| 1/3/2017 | David Pendarvis | Insider | Sell | 6,365 | $61.95 | $394,311.75 | 84,261 | |
| 12/5/2016 | David Pendarvis | Insider | Sell | 6,365 | $60.00 | $381,900.00 | 84,261 | |
| 12/5/2016 | Peter C Farrell | Director | Sell | 20,000 | $59.83 | $1,196,600.00 | 372,407 | |
| 11/4/2016 | Peter C Farrell | Director | Sell | 20,000 | $57.28 | $1,145,600.00 | 367,978 | |
| 11/3/2016 | David Pendarvis | Insider | Sell | 6,033 | $57.79 | $348,647.07 | | |
| 10/18/2016 | James Hollingshead | Insider | Sell | 1,967 | $64.71 | $127,284.57 | 45,513 | |
| 10/17/2016 | James Hollingshead | Insider | Sell | 5,264 | $64.43 | $339,159.52 | 52,744 | |
| 10/17/2016 | Michael J Farrell | CEO | Sell | 5,975 | $64.25 | $383,893.75 | 203,781 | |
| 10/4/2016 | Peter C Farrell | Director | Sell | 20,000 | $64.70 | $1,294,000.00 | 364,063 | |
| 10/3/2016 | David Pendarvis | Insider | Sell | 6,000 | $63.95 | $383,700.00 | 87,061 | |
| 9/15/2016 | Michael J. Farrell | CEO | Sell | 5,975 | $64.84 | $387,419.00 | | |
| 9/6/2016 | David Pendarvis | Insider | Sell | 6,000 | $67.18 | $403,080.00 | 87,061 | |
| 9/6/2016 | Peter C Farrell | Director | Sell | 20,000 | $67.29 | $1,345,800.00 | 367,978 | |
| 8/19/2016 | Gary W Pace | Director | Sell | 36,000 | $69.93 | $2,517,480.00 | 129,158 | |
| 8/17/2016 | Ronald R Taylor | Director | Buy | 2,487 | $69.13 | $171,926.31 | 16,729 | |
| 8/16/2016 | Ronald R Taylor | Director | Sell | 23,102 | $69.25 | $1,599,813.50 | 16,729 | |
| 8/15/2016 | Michael J. Farrell | CEO | Sell | 5,975 | $70.41 | $420,699.75 | | |
| 8/11/2016 | Brett Sandercock | CFO | Sell | 35,000 | $70.50 | $2,467,500.00 | | |
| 8/10/2016 | Richard Sulpizio | Director | Sell | 36,000 | $70.15 | $2,525,400.00 | 101,887 | |
| 8/8/2016 | John P Wareham | Director | Sell | 24,390 | $70.32 | $1,715,104.80 | 37,390 | |
| 8/4/2016 | Peter C Farrell | Director | Sell | 20,000 | $69.16 | $1,383,200.00 | 367,978 | |
| 8/3/2016 | David Pendarvis | Insider | Sell | 6,000 | $68.86 | $413,160.00 | 80,512 | |
| 7/15/2016 | Michael J Farrell | CEO | Sell | 5,975 | $65.03 | $388,554.25 | 154,814 | |
| 7/14/2016 | James Hollingshead | Insider | Sell | 2,753 | $65.02 | $179,000.06 | 40,669 | |
| 7/7/2016 | Peter C Farrell | Director | Sell | 20,000 | $63.62 | $1,272,400.00 | 367,978 | |
| 7/5/2016 | David Pendarvis | Insider | Sell | 6,000 | $63.62 | $381,720.00 | 80,512 | |
| 6/15/2016 | James Hollingshead | Insider | Sell | 4,458 | $59.40 | $264,805.20 | 43,422 | |
| 6/15/2016 | Michael J Farrell | CEO | Sell | 5,975 | $59.63 | $356,289.25 | 154,814 | |
| 6/6/2016 | Peter C Farrell | Director | Sell | 20,000 | $59.82 | $1,196,400.00 | 367,978 | |
| 6/3/2016 | David Pendarvis | Insider | Sell | 6,000 | $59.41 | $356,460.00 | 80,512 | |
| 5/16/2016 | Michael J Farrell | CEO | Sell | 5,975 | $57.64 | $344,399.00 | 154,723 | |
| 5/4/2016 | Peter C Farrell | Director | Sell | 20,000 | $55.90 | $1,118,000.00 | 367,978 | |
| 5/3/2016 | David Pendarvis | Insider | Sell | 6,000 | $56.02 | $336,120.00 | 80,287 | |
| 4/15/2016 | Michael J Farrell | CEO | Sell | 5,975 | $59.34 | $354,556.50 | 154,723 | |
| 4/4/2016 | David Pendarvis | Insider | Sell | 6,000 | $58.70 | $352,200.00 | 80,287 | |
| 4/4/2016 | Peter C Farrell | Director | Sell | 20,000 | $57.51 | $1,150,200.00 | 367,978 | |
| 3/15/2016 | James Hollingshead | Insider | Sell | 4,500 | $58.57 | $263,565.00 | 47,569 | |
| 3/15/2016 | Michael J Farrell | CEO | Sell | 5,975 | $58.57 | $349,955.75 | 150,852 | |
| 3/11/2016 | Gary W Pace | Director | Sell | 36,000 | $60.00 | $2,160,000.00 | 129,158 | |
| 3/4/2016 | Peter C Farrell | Director | Sell | 20,000 | $57.51 | $1,150,200.00 | 367,978 | |
| 3/3/2016 | David Pendarvis | Insider | Sell | 6,000 | $57.26 | $343,560.00 | 80,287 | |
| 2/29/2016 | Anne Reiser | Insider | Sell | 1,946 | $57.06 | $111,038.76 | 76,300 | |
| 2/26/2016 | Brett Sandercock | CFO | Sell | 30,000 | $57.61 | $1,728,300.00 | 132,136 | |
| 2/26/2016 | Richard Sulpizio | Director | Sell | 36,000 | $57.88 | $2,083,680.00 | 101,887 | |
| 2/25/2016 | Peter C Farrell | Director | Sell | 139,980 | $57.31 | $8,022,253.80 | 347,978 | |
| 2/16/2016 | Michael J. Farrell | CEO | Sell | 5,975 | $58.20 | $347,745.00 | 144,878 | |
| 2/4/2016 | Peter C. Farrell | Director | Sell | 20,000 | $57.70 | $1,154,000.00 | 347,978 | |
| 2/3/2016 | David Pendarvis | insider | Sell | 6,000 | $57.43 | $344,580.00 | 74,287 | |
| 1/27/2016 | Franz Kozich | Director | Buy | 60,000 | $0.0350 | $2,100.00 | | |
| 1/15/2016 | Michael J. Farrell | CEO | Sell | 5,975 | $53.07 | $317,093.25 | 144,878 | |
| 1/4/2016 | David Pendarvis | insider | Sell | 6,000 | $52.16 | $312,960.00 | 74,287 | |
| 1/4/2016 | Peter C. Farrell | Director | Sell | 20,000 | $52.22 | $1,044,400.00 | 347,978 | |
| 1/4/2016 | Robert Andrew Douglas | COO | Sell | 6,337 | $52.97 | $335,670.89 | 31,304 | |
| 12/15/2015 | James Hollingshead | Insider | Sell | 4,500 | $55.95 | $251,775.00 | 52,069 | |
| 12/3/2015 | David Pendarvis | insider | Sell | 6,000 | $59.38 | $356,280.00 | 74,287 | |
| 12/1/2015 | Robert Andrew Douglas | COO | Sell | 6,333 | $59.77 | $378,523.41 | 31,304 | |
| 11/25/2015 | Warren Russell Hawkins | Director | Buy | 15,000 | $0.0550 | $825.00 | | |
| 11/24/2015 | Warren Russell Hawkins | Director | Buy | 3,000 | $0.0550 | $165.00 | | |
| 11/20/2015 | Christopher G Roberts | Director | Sell | 12,000 | $59.03 | $708,360.00 | 109,610 | |
| 11/16/2015 | Michael J. Farrell | CEO | Sell | 5,975 | $57.03 | $340,754.25 | 144,878 | |
| 11/12/2015 | Donald Darkin | insider | Sell | 25,442 | $57.72 | $1,468,512.24 | 13,684 | |
| 11/2/2015 | Robert Andrew Douglas | COO | Sell | 6,333 | $57.60 | $364,780.80 | 68,391 | |
| 10/27/2015 | Anne Reiser | insider | Sell | 3,000 | $57.01 | $171,030.00 | 83,214 | |
| 10/15/2015 | Michael J. Farrell | CEO | Sell | 5,975 | $55.35 | $330,716.25 | 172,370 | |
| 10/5/2015 | David Pendarvis | insider | Sell | 5,500 | $52.47 | $288,585.00 | 77,180 | |
| 10/5/2015 | Robert Andrew Douglas | COO | Sell | 6,333 | $52.13 | $330,139.29 | 68,179 | |
| 10/1/2015 | Peter C. Farrell | Chairman | Sell | 27,169 | $50.93 | $1,383,717.17 | 289,826 | |
| 9/15/2015 | James Hollingshead | Insider | Sell | 4,455 | $50.67 | $225,734.85 | 67,680 | |
| 9/15/2015 | Michael J. Farrell | CEO | Sell | 5,975 | $50.89 | $304,067.75 | 172,370 | |
| 9/3/2015 | David Pendarvis | insider | Sell | 5,500 | $51.78 | $284,790.00 | 77,180 | |
| 9/3/2015 | Robert Andrew Douglas | COO | Sell | 6,333 | $52.04 | $329,569.32 | 75,316 | |
| 9/1/2015 | Peter C. Farrell | Chairman | Sell | 36,000 | $50.82 | $1,829,520.00 | 289,826 | |
| 8/28/2015 | Anne Reiser | insider | Sell | 6,000 | $52.26 | $313,560.00 | 83,214 | |
| 8/27/2015 | Richard Sulpizio | Director | Sell | 10,860 | $51.83 | $562,873.80 | 61,527 | |
| 8/17/2015 | Michael J Farrell | CEO | Sell | 5,975 | $55.54 | $331,851.50 | | |
| 7/15/2015 | Michael J Farrell | CEO | Sell | 5,975 | $57.59 | $344,100.25 | | |
| 7/6/2015 | David Pendarvis | Insider | Sell | 5,500 | $55.19 | $303,545.00 | | |
| 7/1/2015 | Peter C Farrell | Chairman | Sell | 36,000 | $55.61 | $2,001,960.00 | | |
| 7/1/2015 | Robert Andrew Douglas | COO | Sell | 6,333 | $56.59 | $358,384.47 | | |
| 6/15/2015 | Michael J Farrell | CEO | Sell | 5,975 | $57.87 | $345,773.25 | | |
| 6/3/2015 | David Pendarvis | Insider | Sell | 5,500 | $59.41 | $326,755.00 | | |
| 6/1/2015 | Peter C Farrell | Chairman | Sell | 36,000 | $59.25 | $2,133,000.00 | | |
| 6/1/2015 | Robert Andrew Douglas | COO | Sell | 6,333 | $59.22 | $375,040.26 | | |
| 5/4/2015 | David Pendarvis | Insider | Sell | 5,500 | $65.10 | $358,050.00 | | |
| 4/6/2015 | David Pendarvis | Insider | Sell | 5,500 | $72.60 | $399,300.00 | | |
| 4/1/2015 | Peter C Farrell | Chairman | Sell | 36,000 | $70.70 | $2,545,200.00 | | |
| 4/1/2015 | Robert Andrew Douglas | COO | Sell | 6,333 | $70.67 | $447,553.11 | | |
| 3/27/2015 | Warren Russell Hawkins | Director | Buy | 10,000 | $0.09 | $900.00 | | |
| 3/26/2015 | Warren Russell Hawkins | Director | Buy | 10,000 | $0.08 | $800.00 | | |
| 3/16/2015 | Anne Reiser | Insider | Sell | 4,000 | $69.10 | $276,400.00 | | |
| 3/16/2015 | Michael J Farrell | CEO | Sell | 5,975 | $69.10 | $412,872.50 | | |
| 3/9/2015 | Anne Reiser | Insider | Sell | 3,000 | $66.75 | $200,250.00 | | |
| 3/2/2015 | Peter C Farrell | Chairman | Sell | 36,000 | $64.64 | $2,327,040.00 | | |
| 3/2/2015 | Robert Andrew Douglas | COO | Sell | 6,333 | $64.39 | $407,781.87 | | |
| 2/17/2015 | Anne Reiser | Insider | Sell | 5,000 | $66.11 | $330,550.00 | | |
| 2/5/2015 | David Pendarvis | Insider | Sell | 5,500 | $62.35 | $342,925.00 | | |
| 2/4/2015 | John P Wareham | Director | Sell | 36,000 | $63.49 | $2,285,640.00 | | |
| 2/3/2015 | Brett Sandercock | CFO | Sell | 18,670 | $62.82 | $1,172,849.40 | | |
| 2/3/2015 | Robert Andrew Douglas | COO | Sell | 6,333 | $62.35 | $394,862.55 | | |
| 2/2/2015 | Peter C Farrell | Chairman | Sell | 36,000 | $61.97 | $2,230,920.00 | | |
| 1/26/2015 | Gary W Pace | Director | Sell | 48,000 | $66.77 | $3,204,960.00 | | |
| 1/5/2015 | David Pendarvis | Insider | Sell | 5,500 | $57.09 | $313,995.00 | | |
| 1/2/2015 | Peter C Farrell | Chairman | Sell | 36,000 | $56.99 | $2,051,640.00 | | |
| 1/2/2015 | Robert Andrew Douglas | COO | Sell | 8,000 | $56.99 | $455,920.00 | | |
| 12/1/2014 | Peter C Farrell | Chairman | Sell | 36,000 | $53.28 | $1,918,080.00 | | |
| 12/1/2014 | Robert Andrew Douglas | COO | Sell | 8,000 | $52.93 | $423,440.00 | | |
| 11/18/2014 | Peter C Farrell | Chairman | Sell | 36,000 | $52.39 | $1,886,040.00 | | |
| 11/3/2014 | David Pendarvis | Insider | Sell | 3,557 | $52.00 | $184,964.00 | | |
| 11/3/2014 | Robert Andrew Douglas | COO | Sell | 8,000 | $51.84 | $414,720.00 | | |
| 10/29/2014 | Peter C Farrell | Chairman | Sell | 119,204 | $51.84 | $6,179,535.36 | | |
| 10/3/2014 | David Pendarvis | Insider | Sell | 5,000 | $49.84 | $249,200.00 | | |
| 10/1/2014 | Robert Andrew Douglas | COO | Sell | 8,000 | $49.11 | $392,880.00 | | |
| 9/15/2014 | Michael J Farrell | CEO | Sell | 3,200 | $52.41 | $167,712.00 | | |
| 9/5/2014 | Brett Sandercock | CFO | Sell | 10,000 | $52.99 | $529,900.00 | | |
| 9/3/2014 | Brett Sandercock | CFO | Sell | 10,000 | $53.23 | $532,300.00 | | |
| 9/3/2014 | David Pendarvis | Insider | Sell | 5,000 | $53.23 | $266,150.00 | | |
| 8/22/2014 | Anne Reiser | Insider | Sell | 3,000 | $53.37 | $160,110.00 | | |
| 8/4/2014 | David Pendarvis | Insider | Sell | 5,000 | $49.12 | $245,600.00 | | |
| 8/1/2014 | Peter C Farrell | Director | Sell | 25,000 | $49.04 | $1,226,000.00 | | |
| 8/1/2014 | Robert Andrew Douglas | COO | Sell | 8,000 | $48.95 | $391,600.00 | | |
| 7/15/2014 | Michael J Farrell | CEO | Sell | 3,200 | $49.22 | $157,504.00 | | |
| 7/3/2014 | David Pendarvis | Insider | Sell | 5,000 | $50.04 | $250,200.00 | | |
| 7/1/2014 | Peter C Farrell | Director | Sell | 25,000 | $50.09 | $1,252,250.00 | | |
| 7/1/2014 | Robert Andrew Douglas | COO | Sell | 8,000 | $50.11 | $400,880.00 | | |
| 6/16/2014 | Michael J Farrell | CEO | Sell | 3,200 | $53.20 | $170,240.00 | | |
| 6/3/2014 | David Pendarvis | Insider | Sell | 5,000 | $49.76 | $248,800.00 | | |
| 6/2/2014 | Peter C Farrell | Director | Sell | 25,000 | $49.57 | $1,239,250.00 | | |
| 6/2/2014 | Robert Andrew Douglas | COO | Sell | 8,000 | $50.11 | $400,880.00 | | |
| 5/29/2014 | Christopher G Roberts | Director | Sell | 25,000 | $49.73 | $1,243,250.00 | | |
| 5/15/2014 | Michael Farrell | CEO | Sell | 3,700 | $50.54 | $186,998.00 | 106,655 | |
| 5/13/2014 | John Wareham | Director | Sell | 18,000 | $51.00 | $918,000.00 | 13,000 | |
| 5/8/2014 | Brett Sandercock | CFO | Sell | 5,000 | $50.00 | $250,000.00 | 66,423 | |
| 5/6/2014 | Brett Sandercock | CFO | Sell | 4,290 | $50.00 | $214,500.00 | 71,423 | |
| 5/1/2014 | Peter Farrell | Director | Sell | 25,000 | $49.80 | $1,245,000.00 | 304,990 | |
| 5/1/2014 | Robert Andrew Douglas | COO | Sell | 8,000 | $49.75 | $398,000.00 | | |
| 4/29/2014 | David Pendarvis | Insider | Sell | 15,000 | $50.01 | $750,150.00 | 68,956 | |
| 4/21/2014 | Peter Farrell | Director | Sell | 75,000 | $48.01 | $3,600,750.00 | 304,990 | |
| 4/4/2014 | David Pendarvis | Insider | Sell | 5,000 | $44.95 | $224,750.00 | 68,956 | |
| 2/12/2014 | Brett Sandercock | CFO | Sell | 10,687 | $46.00 | $491,602.00 | 84,215 | |
| 1/9/2014 | Peter Farrell | Director | Sell | 25,000 | $48.00 | $1,200,000.00 | 489,876 | |
| 12/2/2013 | Robert Andrew Douglas | COO | Sell | 8,000 | $49.10 | $392,800.00 | 100,572 | |
| 11/20/2013 | Brett Sandercock | CFO | Sell | 15,000 | $51.06 | $765,900.00 | 94,902 | |
| 11/20/2013 | James Hollingshead | Insider | Sell | 4,000 | $51.24 | $204,960.00 | 26,285 | |
| 11/12/2013 | Donald Darkin | Insider | Sell | 31,063 | $50.04 | $1,554,392.52 | 18,588 | |
| 10/29/2013 | David Pendarvis | Insider | Sell | 37,744 | $50.42 | $1,903,052.48 | | |
| 10/1/2013 | Peter C Farrell | Director | Sell | 25,000 | $53.21 | $1,330,250.00 | | |
| 10/1/2013 | Robert Andrew Douglas | COO | Sell | 8,000 | $53.20 | $425,600.00 | | |
| 9/9/2013 | Gary W Pace | Director | Sell | 12,000 | $50.05 | $600,600.00 | | |
| 9/5/2013 | Peter C Farrell | Director | Sell | 25,000 | $48.00 | $1,200,000.00 | | |
| 9/3/2013 | Robert Andrew Douglas | COO | Sell | 8,000 | $47.51 | $380,080.00 | 123,892 | |
| 8/28/2013 | Michael Quinn | Director | Sell | 48,000 | $48.34 | $2,320,320.00 | 880,000 | |
| 8/27/2013 | Brett Sandercock | CFO | Sell | 5,000 | $49.00 | $245,000.00 | 109,012 | |
| 8/26/2013 | Christopher Roberts | Director | Sell | 10,000 | $49.49 | $494,900.00 | 90,000 | |
| 8/1/2013 | Robert Andrew Douglas | COO | Sell | 8,000 | $48.57 | $388,560.00 | | |
| 6/3/2013 | Robert Andrew Douglas | COO | Sell | 8,000 | $47.96 | $383,680.00 | | |
| 5/24/2013 | Christopher G Roberts | Director | Sell | 20,000 | $49.45 | $989,000.00 | | |
| 5/22/2013 | John P Wareham | Director | Sell | 18,000 | $50.20 | $903,600.00 | | |
| 5/13/2013 | Michael A Quinn | Director | Sell | 15,000 | $50.94 | $764,100.00 | | |
| 5/8/2013 | Brett Sandercock | CFO | Sell | 28,000 | $48.97 | $1,371,160.00 | | |
| 2/4/2013 | Robert Andrew Douglas | COO | Sell | 8,000 | $44.14 | $353,120.00 | | |
| 8/8/2012 | Michael J Farrell | Insider | Sell | 30,000 | $35.58 | $1,067,400.00 | | |
(Data available from 1/1/2013 forward)
ResMed (NYSE RMD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | ResMed (RMD) Stock Rating Lowered by UBS
www.americanbankingnews.com - April 24 at 9:29 AM |
 | UBS & Macquarie deliver ratings on ResMed Inc. ahead of profit report
www.fool.com.au - April 24 at 8:48 AM |
 | Analysis: Positioning to Benefit within Korn/Ferry International, ResMed, Donaldson, Ollie's Bargain Outlet, VSE, and ...
globenewswire.com - April 23 at 8:39 AM |
 | Medical Equipment Stocks' Research Reports Released on Myomo, Neovasc, ResMed, and Wright Medical
www.prnewswire.com - April 23 at 8:39 AM |
 | Analysis: Positioning to Benefit within Korn/Ferry International, ResMed, Donaldson, Ollie's Bargain Outlet, VSE, and STARWOOD PROPERTY TRUST, INC — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - April 23 at 8:39 AM |
| Zacks: Brokerages Expect ResMed Inc. (RMD) to Announce $0.83 EPS
www.americanbankingnews.com - April 23 at 7:16 AM |
 | BRIEF-Resmed Says Co Entered Certain Amended And Restated Credit Agreement, Dated As Of Closing Date
www.reuters.com - April 20 at 8:58 AM |
| 3 reasons why I'm bullish on ResMed Inc. (CHESS)
www.fool.com.au - April 20 at 8:58 AM |
| ResMed (RMD) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - April 19 at 1:21 AM |
 | Form 4 RESMED INC For: Apr 16 Filed by: Sandercock Brett
www.streetinsider.com - April 18 at 8:51 AM |
| William Blair Reiterates Outperform Rating for ResMed (RMD)
www.americanbankingnews.com - April 18 at 8:36 AM |
| ResMed Inc. (RMD) CFO Brett Sandercock Sells 2,000 Shares
www.americanbankingnews.com - April 17 at 10:33 PM |
| ResMed (RMD) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - April 16 at 5:24 PM |
| Bank of America Lowers ResMed (RMD) to Neutral
www.americanbankingnews.com - April 14 at 11:49 AM |
| ResMed (RMD) Given "Sell" Rating at Needham & Company LLC
www.americanbankingnews.com - April 14 at 10:35 AM |
| ResMed (RMD) Downgraded to "Neutral" at Credit Suisse Group
www.americanbankingnews.com - April 14 at 10:35 AM |
| ResMed (RMD) Upgraded by Citigroup to "Buy"
www.americanbankingnews.com - April 14 at 10:35 AM |
| ResMed (RMD) PT Raised to $70.00
www.americanbankingnews.com - April 14 at 9:37 AM |
| ResMed (RMD) versus Baxter International (BAX) Financial Analysis
www.americanbankingnews.com - April 11 at 9:59 AM |
 | Australia and New Zealand at healthcare cutting edge
www.ft.com - April 10 at 5:02 PM |
| ResMed (RMD) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - April 9 at 2:58 PM |
| ResMed Inc. (RMD) Expected to Post Quarterly Sales of $562.33 Million
www.americanbankingnews.com - April 8 at 3:58 AM |
| ResMed Inc. (RMD) Expected to Post Earnings of $0.83 Per Share
www.americanbankingnews.com - April 6 at 9:19 AM |
| JPMorgan Chase Boosts ResMed (RMD) Price Target to $73.00
www.americanbankingnews.com - April 4 at 1:23 PM |
| ResMed (RMD) Rating Lowered to Neutral at Citigroup
www.americanbankingnews.com - April 4 at 12:49 PM |
| Top broker slaps $175 price target on CSL Limited shares
www.fool.com.au - April 4 at 8:53 AM |
| ResMed Inc. (RMD) Insider James Hollingshead Sells 600 Shares
www.americanbankingnews.com - April 3 at 10:45 PM |
| ResMed Hires Bobby Ghoshal as First Chief Technology Officer
finance.yahoo.com - April 2 at 9:17 AM |
| ResMed Inc. (RMD) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 31 at 3:34 PM |
| ResMed to Announce Third Quarter Fiscal Year 2018 Results
finance.yahoo.com - March 29 at 5:00 PM |
| Medical Equipment Stocks' Research Reports Released on Medtronic, Neovasc, ResMed, and Wright Medical
www.prnewswire.com - March 27 at 9:08 AM |
| Needham & Company LLC Upgrades ResMed (RMD) to "Hold"
www.americanbankingnews.com - March 26 at 7:43 PM |
| ResMed (RMD) PT Raised to $90.00
www.americanbankingnews.com - March 26 at 7:41 PM |
| Northland Securities Upgrades ResMed (RMD) to Market Perform
www.americanbankingnews.com - March 26 at 7:08 PM |
| Here's Why You Must Add ResMed (RMD) to Your Portfolio Now
finance.yahoo.com - March 26 at 4:49 PM |
| Zacks: Analysts Expect ResMed Inc. (RMD) Will Post Quarterly Sales of $562.33 Million
www.americanbankingnews.com - March 22 at 5:34 AM |
| Brett Sandercock Sells 2,000 Shares of ResMed Inc. (RMD) Stock
www.americanbankingnews.com - March 19 at 1:34 PM |
 | Global Respiratory Care Devices Market Opportunities 2018: AstraZeneca PLC, ResMed, 3M, Medtronic, GE Healthcare, GlaxoSmithKline
www.marketwatch.com - March 14 at 9:27 AM |
| ResMed (RMD) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 8 at 12:52 PM |
 | ResMed (RMD) Rides High on Robust Global Growth & Innovation - Nasdaq
www.nasdaq.com - March 7 at 5:54 PM |
| Insider Selling: ResMed Inc. (RMD) Insider Sells 2,810 Shares of Stock
www.americanbankingnews.com - March 7 at 3:15 PM |
| Needham & Company LLC Reaffirms Hold Rating for ResMed (RMD)
www.americanbankingnews.com - March 7 at 2:50 PM |
| ResMed Inc. (RMD) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 6 at 3:22 PM |
| ResMed (RMD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 6 at 2:06 PM |
| Head-To-Head Analysis: ResMed (RMD) versus Mindray Medical International (MR)
www.americanbankingnews.com - March 5 at 9:16 PM |
| WINTON GROUP Ltd Acquires 66,102 Shares of ResMed Inc. (RMD)
www.americanbankingnews.com - March 5 at 4:08 PM |
| ResMed Inc. (RMD) Stake Decreased by State of Tennessee Treasury Department
www.americanbankingnews.com - March 5 at 3:28 PM |
| Lombard Odier Asset Management Switzerland SA Has $3.21 Million Holdings in ResMed Inc. (RMD)
www.americanbankingnews.com - March 5 at 11:48 AM |
| Zacks: Analysts Anticipate ResMed Inc. (RMD) Will Announce Quarterly Sales of $562.33 Million
www.americanbankingnews.com - March 5 at 7:00 AM |
| American International Group Inc. Grows Position in ResMed Inc. (RMD)
www.americanbankingnews.com - March 5 at 4:24 AM |
ResMed (NYSE:RMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ResMed (NYSE:RMD) Income Statement, Balance Sheet and Cash Flow Statement
ResMed (NYSE RMD) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
